205 related articles for article (PubMed ID: 1317149)
1. In vitro activities of three of the newer quinolones against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1992 Jan; 36(1):239-43. PubMed ID: 1317149
[TBL] [Abstract][Full Text] [Related]
2. In vitro activity of Bay Y3118 against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Antimicrob Agents Chemother; 1993 Nov; 37(11):2509-13. PubMed ID: 8285647
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of DU-6859a against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of temafloxacin against anaerobic bacteria: a comparative study.
Finegold SM; Molitoris E; Reeves D; Wexler HM
J Antimicrob Chemother; 1991 Dec; 28 Suppl C():25-30. PubMed ID: 1664827
[TBL] [Abstract][Full Text] [Related]
5. Comparative activity of ciprofloxacin, ofloxacin, sparfloxacin, temafloxacin, CI-960, CI-990, and WIN 57273 against anaerobic bacteria.
Goldstein EJ; Citron DM
Antimicrob Agents Chemother; 1992 May; 36(5):1158-62. PubMed ID: 1324640
[TBL] [Abstract][Full Text] [Related]
6. In-vitro activity of clinafloxacin (CI-960) and PD 131628-2 against anaerobic bacteria.
Wexler HM; Molitoris E; Reeves D; Finegold SM
J Antimicrob Chemother; 1994 Oct; 34(4):579-84. PubMed ID: 7868409
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of grepafloxacin (OPC-17116) against anaerobic bacteria.
Wexler HM; Molitoris E; Finegold SM
Diagn Microbiol Infect Dis; 1994 Jun; 19(2):129-33. PubMed ID: 7805357
[TBL] [Abstract][Full Text] [Related]
8. Increased activity of a new chlorofluoroquinolone, BAY y 3118, compared with activities of ciprofloxacin, sparfloxacin, and other antimicrobial agents against anaerobic bacteria.
Aldridge KE
Antimicrob Agents Chemother; 1994 Jul; 38(7):1671-4. PubMed ID: 7979307
[TBL] [Abstract][Full Text] [Related]
9. Comparative in vitro activities of a new quinolone, WIN 57273, and piperacillin plus tazobactam against anaerobic bacteria.
Venezia RA; Yocum DM; Robbiano EM; Echols RM
Antimicrob Agents Chemother; 1990 Sep; 34(9):1858-61. PubMed ID: 2178340
[TBL] [Abstract][Full Text] [Related]
10. In vitro activities of trovafloxacin against 557 strains of anaerobic bacteria.
Wexler HM; Molitoris E; Molitoris D; Finegold SM
Antimicrob Agents Chemother; 1996 Sep; 40(9):2232-5. PubMed ID: 8878617
[TBL] [Abstract][Full Text] [Related]
11. Patterns of susceptibility to fluoroquinolones among anaerobic bacterial isolates in the United States.
Goldstein EJ
Clin Infect Dis; 1993 Jun; 16 Suppl 4():S377-81. PubMed ID: 8324151
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of quinolones and other antimicrobial agents against anaerobic bacteria.
Nord CE
Clin Infect Dis; 1996 Dec; 23 Suppl 1():S15-8. PubMed ID: 8953101
[TBL] [Abstract][Full Text] [Related]
13. Susceptibilities of 428 gram-positive and -negative anaerobic bacteria to Bay y3118 compared with their susceptibilities to ciprofloxacin, clindamycin, metronidazole, piperacillin, piperacillin-tazobactam, and cefoxitin.
Pankuch GA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1993 Aug; 37(8):1649-54. PubMed ID: 8215278
[TBL] [Abstract][Full Text] [Related]
14. Susceptibility of anaerobic bacteria to PD 131628.
Nord CE; Hagelbäck A
Eur J Clin Microbiol Infect Dis; 1992 Jan; 11(1):68-71. PubMed ID: 1314176
[TBL] [Abstract][Full Text] [Related]
15. In vitro activity of gemifloxacin (SB 265805) against anaerobes.
Goldstein EJ; Citron DM; Warren Y; Tyrrell K; Merriam CV
Antimicrob Agents Chemother; 1999 Sep; 43(9):2231-5. PubMed ID: 10471570
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic system.
Zabinski RA; Vance-Bryan K; Krinke AJ; Walker KJ; Moody JA; Rotschafer JC
Antimicrob Agents Chemother; 1993 Nov; 37(11):2454-8. PubMed ID: 8285633
[TBL] [Abstract][Full Text] [Related]
17. Activity of CP 99,219 compared with those of ciprofloxacin, grepafloxacin, metronidazole, cefoxitin, piperacillin, and piperacillin-tazobactam against 489 anaerobes.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Oct; 38(10):2471-6. PubMed ID: 7840591
[TBL] [Abstract][Full Text] [Related]
18. In vitro activity of the new quinolone BAY y 3118 against anaerobic bacteria.
Nord CE; Lindmark A; Persson I
Eur J Clin Microbiol Infect Dis; 1993 Aug; 12(8):640-2. PubMed ID: 8223667
[TBL] [Abstract][Full Text] [Related]
19. Activity of WY-49605 compared with those of amoxicillin, amoxicillin-clavulanate, imipenem, ciprofloxacin, cefaclor, cefpodoxime, cefuroxime, clindamycin, and metronidazole against 384 anaerobic bacteria.
Spangler SK; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1994 Nov; 38(11):2599-604. PubMed ID: 7872754
[TBL] [Abstract][Full Text] [Related]
20. Comparative in vitro activities of trovafloxacin (CP 99,219) and other antimicrobials against clinically significant anaerobes.
Aldridge KE; Ashcraft D; Bowman KA
Antimicrob Agents Chemother; 1997 Feb; 41(2):484-7. PubMed ID: 9021215
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
